<p>TRANSTHERA-B (02617.HK) announced its 2025 annual performance, reporting a loss of 296 million RMB, compared to a loss of 275 million RMB in the previous year; the loss per share is 0.76 RMB. No dividend is declared. No revenue was generated during the year</p>

159506

562050

<p>TRANSTHERA-B announced its 2025 annual performance, reporting a loss of 296 million RMB (the same below), compared to a loss of 275 million RMB in the previous year; the loss per share is 0.76 RMB. No dividend is declared. No revenue was generated during the year</p>

AASTOCKS

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE STAR Biology and Medicine ETF

TRANSTHERA-B

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

"Performance" TRANSTHERA's annual loss expanded to 296 million RMB